Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | EVP, CFO, Treasurer | March 15, 2024 | March 19, 2024 |
| INSULET CORPPODD · Entity 3516 | SVP and CFO | February 27, 2019 | March 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date March 15, 2024 · Filed March 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 21,329 |
Reported balance
After 2024-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-15 · Grant · Acquired 21,329 · Balance 21,329 F1: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.98 · Expires 2034-03-11 | Direct | 51,682 |
Reported balance
After 2024-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-15 · Grant · Acquired 51,682 · Balance 51,682 F2: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F3: The premium priced stock options vest in three equal annual installments beginning on March 15, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025.
F2: Represents a 10% premium above the closing price of Anika's common stock on the date of grant.
F3: The premium priced stock options vest in three equal annual installments beginning on March 15, 2025.
INSULET CORP
Report date February 27, 2019 · Filed March 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,651 |
Reported balance
After 2019-02-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-02-27 · Sale · Disposed 1,350 · Balance 56,651 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2018. F2: Includes 2,164 restricted stock units granted on February 22, 2017, which vest on February 22, 2020; and 2,685 restricted stock units granted on February 14, 2018, which vest as to one-half of the total units on February 14, 2020 and one-half of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2018.
F2: Includes 2,164 restricted stock units granted on February 22, 2017, which vest on February 22, 2020; and 2,685 restricted stock units granted on February 14, 2018, which vest as to one-half of the total units on February 14, 2020 and one-half of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2024 Filed Mar 19, 2024 21:23 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 51,682 | $0.00 Strike: $27.98 | $0.00 |
DisclosureSEC source: 0001171843-24-001461 · ownership.xml · derivative · entry 2 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,682 Underlying: Common Stock · 51,682 shares Expires 2034-03-11 F2 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F3 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on March 15, 2025. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 21:23 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 21,329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001461 · ownership.xml · derivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,329 Underlying: Common Stock · 21,329 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 8,888 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001304 · ownership.xml · derivative · entry 9 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. F12 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 5,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001304 · ownership.xml · derivative · entry 8 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,749 Underlying: Common Stock · 5,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. F11 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 4,438 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001304 · ownership.xml · derivative · entry 7 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. F10 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 2,610 | $25.79 | $67,311.90 |
DisclosureSEC source: 0001171843-24-001304 · ownership.xml · nonDerivative · entry 6 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,955 F8 · shares: Reflects an aggregate of 2,610 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2024. F9 · price: Reflects the closing price of ANIK common stock on March 11, 2024, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 8,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001304 · ownership.xml · nonDerivative · entry 5 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: Reflects the second vesting installment of RSUs granted on March 11, 2022. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,725 | $25.42 | $43,849.50 |
DisclosureSEC source: 0001171843-24-001304 · ownership.xml · nonDerivative · entry 4 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,677 F6 · shares: Reflects an aggregate of 1,725 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2024. F4 · price: Reflects the closing price of ANIK common stock on March 8, 2024, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 5,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001304 · ownership.xml · nonDerivative · entry 3 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Reflects the first vesting installment of RSUs granted on March 9, 2023. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,303 | $25.42 | $33,122.26 |
DisclosureSEC source: 0001171843-24-001304 · ownership.xml · nonDerivative · entry 2 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,527 F3 · shares: Reflects an aggregate of 1,303 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2024. F4 · price: Reflects the closing price of ANIK common stock on March 8, 2024, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 4,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001304 · ownership.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the third and final vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021. F2 · balance_after: Includes 160 shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan on November 14, 2023. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 3,859 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-005271 · ownership.xml · derivative · entry 3 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning August 10, 2021. F5 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning August 10, 2021. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,133 | $18.58 | $21,051.14 |
DisclosureSEC source: 0001171843-23-005271 · ownership.xml · nonDerivative · entry 2 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,232 F3 · shares: Reflects an aggregate of 1,133 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on August 10, 2023. F4 · price: Reflects the closing price of ANIK common stock on August 10, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 3,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-005271 · ownership.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the third and final vesting installment of Restricted Stock Units (RSUs) granted on August 10, 2020. F2 · balance_after: Includes 668 shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan on May 12, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:47 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 8,888 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001686 · ownership.xml · derivative · entry 3 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,776 Underlying: Common Stock · 8,888 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:47 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 2,609 | $26.10 | $68,094.90 |
DisclosureSEC source: 0001171843-23-001686 · ownership.xml · nonDerivative · entry 2 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,838 F2 · shares: Reflects an aggregate of 2,609 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2023. F3 · price: Reflects the closing price of ANIK common stock on March 10, 2023, the trading day immediately preceding the date on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:47 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 8,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001686 · ownership.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the first vesting installment of Restricted Stock Units (RSUs) granted on March 11, 2022. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:52 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 4,439 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001597 · ownership.xml · derivative · entry 5 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,438 Underlying: Common Stock · 4,439 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. F7 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:52 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 38,475 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001171843-23-001597 · ownership.xml · derivative · entry 4 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,475 Underlying: Common Stock · 38,475 shares Expires 2033-03-09 F5 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F6 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on March 9, 2024. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:52 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 17,624 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001597 · ownership.xml · derivative · entry 3 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,624 Underlying: Common Stock · 17,624 shares Expires not disclosed F4 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:52 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,303 | $26.91 | $35,063.73 |
DisclosureSEC source: 0001171843-23-001597 · ownership.xml · nonDerivative · entry 2 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,559 F2 · shares: Reflects an aggregate of 1,303 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2023. F3 · price: Reflects the closing price of ANIK common stock on March 9, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:52 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 4,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001597 · ownership.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the second vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 20:11 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 3,859 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-005617 · ownership.xml · derivative · entry 2 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,859 Underlying: Common Stock · 3,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning August 10, 2021. F3 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning August 10, 2021. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 20:11 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 3,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-005617 · ownership.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the second vesting installment of Restricted Stock Units (RSUs) granted on August 10, 2020. The 3,859 shares resulting from the RSU vest were retained in full as a result of Mr. Levitz's election to pay cash to cover the applicable taxes resulting from the RSU vest. F2 · balance_after: Includes 640 shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan on May 13, 2022. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 13:00 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | PurchaseCommon Stock | 4,000 | $24.62 | $98,476.00 |
DisclosureSEC source: 0001171843-22-001832 · ownership.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,924 F1 · price: On March 11, 2022, Mr. Levitz purchased 4,000 shares in multiple trades ranging from $24.30 to $24.74. The price reported above reflects the weighted average purchase price. Mr. Levitz undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 21:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 38,979 | $0.00 Strike: $28.14 | $0.00 |
DisclosureSEC source: 0001171843-22-001905 · ownership.xml · derivative · entry 2 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,979 Underlying: Common Stock · 38,979 shares Expires 2032-03-11 F2 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F3 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on March 11, 2023. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 21:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 26,664 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-001905 · ownership.xml · derivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,664 Underlying: Common Stock · 26,664 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:36 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 4,438 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-001812 · ownership.xml · derivative · entry 2 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,877 Underlying: Common Stock · 4,438 shares Expires not disclosed F2 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. F2 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:36 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 4,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-001812 · ownership.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the first vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021. The 4,438 shares resulting from the RSU vest were retained in full as a result of Mr. Levitz's election to pay cash to cover the applicable taxes resulting from the RSU vest. Read SEC document |
| August 12, 2021 Filed Aug 13, 2021 16:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | PurchaseCommon Stock | 777 | $40.21 | $31,239.29 |
DisclosureSEC source: 0001171843-21-005933 · ownership.xml · nonDerivative · entry 2 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,486 F2 · price: On August 12, 2021, Mr. Levitz purchased 777 shares in multiple trades ranging from $40.07 to $40.41. The price reported above reflects the weighted average purchase price. Mr. Levitz undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 16:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | PurchaseCommon Stock | 2,850 | $40.21 | $114,587.10 |
DisclosureSEC source: 0001171843-21-005933 · ownership.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,709 F1 · price: On August 11, 2021, Mr. Levitz purchased 2,850 shares in multiple trades ranging from $39.85 to $40.50. The price reported above reflects the weighted average purchase price. Mr. Levitz undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 20:31 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 3,859 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-005897 · ownership.xml · derivative · entry 2 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,718 Underlying: Common Stock · 3,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning August 10, 2021. F2 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning August 10, 2021. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 20:31 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 3,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-005897 · ownership.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the first vesting installment of RSUs granted on August 10, 2020. The 3,859 shares resulting from the RSU vest were retained in full as a result of Mr. Levitz's election to pay cash to cover the applicable taxes resulting from the RSU vest. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:12 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 33,363 | $0.00 Strike: $37.40 | $0.00 |
DisclosureSEC source: 0001171843-21-001711 · ownership.xml · derivative · entry 2 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,363 Underlying: Common Stock · 33,363 shares Expires 2031-03-09 F2 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F3 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on March 9, 2022. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:12 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 13,315 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-001711 · ownership.xml · derivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,315 Underlying: Common Stock · 13,315 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:10 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 57,145 | $0.00 Strike: $34.55 | $0.00 |
DisclosureSEC source: 0001171843-20-005857 · ownership.xml · derivative · entry 2 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,145 Underlying: Common Stock · 57,145 shares Expires 2030-08-10 F2 · derivative.exercise_date: The stock options vest in three equal annual installments beginning August 10, 2021. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:10 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 11,577 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-005857 · ownership.xml · derivative · entry 1 Levitz Michael L · CIK 0001468019 · EVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,577 Underlying: Common Stock · 11,577 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning August 10, 2021. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning August 10, 2021. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 01:44 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 1,350 | $92.01 | $124,213.50 |
DisclosureSEC source: 0001127602-19-009058 · form4.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,651 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2018. F2 · balance_after: Includes 2,164 restricted stock units granted on February 22, 2017, which vest on February 22, 2020; and 2,685 restricted stock units granted on February 14, 2018, which vest as to one-half of the total units on February 14, 2020 and one-half of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| February 24, 2019 Filed Feb 27, 2019 00:08 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 2,978 | $87.60 | $260,872.80 |
DisclosureSEC source: 0001127602-19-008494 · form4.xml · nonDerivative · entry 2 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,001 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. F3 · balance_after: Includes 2,164 restricted stock units granted on February 22, 2017, which vest on February 22, 2020; and 2,685 restricted stock units granted on February 14, 2018, which vest as to one-half of the total units on February 14, 2020 and one-half of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:08 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 637 | $87.60 | $55,801.20 |
DisclosureSEC source: 0001127602-19-008494 · form4.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,979 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. F2 · balance_after: Includes 3,418 restricted stock units granted on February 24, 2016, which vest on February 24, 2019; 5,980 performance share units granted on February 24, 2016, which vest on February 24, 2019; and 2,164 restricted stock units granted on February 22, 2017, which vest on February 22, 2020; and 2,685 restricted stock units granted on February 14, 2018, which vest as to one-half of the total units on February 14, 2020 and one-half of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 22:19 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 446 | $84.83 | $37,834.18 |
DisclosureSEC source: 0001127602-19-006921 · form4.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,616 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. F2 · balance_after: Includes 3,418 restricted stock units granted on February 24, 2016, which vest on February 24, 2019; 5,982 performance share units granted on February 24, 2016, which vest on February 24, 2019; and 4,328 restricted stock units granted on February 22, 2017, which vest one-half of the total units on February 22, 2019 and one-half of the total units on February 22, 2020; and 2,685 restricted stock units granted on February 14, 2018, which vest as to one-half of the total units on February 14, 2020 and one-half of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F3 · balance_after: Includes the following shares acquired under the Insulet Corporation 2007 Employee Stock Purchase Plan; 263 shares purchased on May 31, 2018 and 67 shares purchased on November 30, 2018. Read SEC document |
| May 04, 2018 Filed May 8, 2018 22:16 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 6,376 | $83.88 | $534,818.88 |
DisclosureSEC source: 0001127602-18-016669 · form4.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,270 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. F2 · balance_after: Includes 3,418 restricted stock units granted on February 24, 2016, which vest on February 24, 2019; 5,982 performance share units granted on February 24, 2016, which vest on February 24, 2019; and 4,328 restricted stock units granted on February 22, 2017, which vest one-half of the total units on February 22, 2019 and one-half of the total units on February 22, 2020; and 4,027 restricted stock units granted on February 14, 2018, which vest as to one-third of the total units on February 14, 2019, one-third of the total units on February 14, 2020 and one-third of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| February 24, 2018 Filed Feb 27, 2018 23:22 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 1,007 | $75.55 | $76,078.85 |
DisclosureSEC source: 0001127602-18-008810 · form4.xml · nonDerivative · entry 2 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,646 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. F2 · balance_after: Includes 14,343 restricted stock units granted on May 4, 2015, which vest on May 4, 2018; 3,418 restricted stock units granted on February 24, 2016, which vest on February 24, 2019; 5,982 performance share units granted on February 24, 2016, which vest on February 24, 2019; and 4,328 restricted stock units granted on February 22, 2017, which vest one-half of the total units on February 22, 2019 and one-half of the total units on February 22, 2020; and 4,027 restricted stock units granted on February 14, 2018, which vest as to one-third of the total units on February 14, 2019, one-third of the total units on February 14, 2020 and one-third of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F3 · balance_after: Includes 462 shares acquired on November 30, 2017 under the Insulet Corporation 2007 Employee Stock Purchase Plan. Read SEC document |
| February 24, 2018 Filed Feb 27, 2018 23:22 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 1,762 | $75.55 | $133,119.10 |
DisclosureSEC source: 0001127602-18-008810 · form4.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,653 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. F2 · balance_after: Includes 14,343 restricted stock units granted on May 4, 2015, which vest on May 4, 2018; 3,418 restricted stock units granted on February 24, 2016, which vest on February 24, 2019; 5,982 performance share units granted on February 24, 2016, which vest on February 24, 2019; and 4,328 restricted stock units granted on February 22, 2017, which vest one-half of the total units on February 22, 2019 and one-half of the total units on February 22, 2020; and 4,027 restricted stock units granted on February 14, 2018, which vest as to one-third of the total units on February 14, 2019, one-third of the total units on February 14, 2020 and one-third of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F3 · balance_after: Includes 462 shares acquired on November 30, 2017 under the Insulet Corporation 2007 Employee Stock Purchase Plan. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 01:07 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 677 | $80.46 | $54,471.42 |
DisclosureSEC source: 0001127602-18-008531 · form4.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,415 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. F2 · balance_after: Includes 14,343 restricted stock units granted on May 4, 2015, which vest on May 4, 2018; 6,836 restricted stock units granted on February 24, 2016, which vest one-half of the total units on February 24, 2018 and one-half of the total units on February 24, 2019; 11,962 performance share units granted on February 24, 2016, which vest as to one-half of the total units on February 24, 2018 and one-half of the total units on February 24, 2019; and 4,328 restricted stock units granted on February 22, 2017, which vest one-half of the total units on February 22, 2019 and one-half of the total units on February 22, 2020; and 4,027 restricted stock units granted on February 14, 2018, which vest as to one-third of the total units on February 14, 2019, one-third of the total units on February 14, 2020 and one-third of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F3 · balance_after: Includes 462 shares acquired on November 30, 2017 under the Insulet Corporation 2007 Employee Stock Purchase Plan. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 01:08 UTC | INSULET CORP PODD · Entity 3516 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,492 | $0.00 Strike: $74.50 | $0.00 |
DisclosureSEC source: 0001127602-18-006482 · form4.xml · derivative · entry 3 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,492 Underlying: Common Stock · 10,492 shares Expires 2028-02-14 F5 · derivative.exercise_date: This option is subject to a four-year vesting period with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 01:08 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 4,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006482 · form4.xml · nonDerivative · entry 2 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,092 F4 · shares: The 4,027 restricted stock units vest one-third of the total units on February 14, 2019, one-third of the total units on February 14, 2020 and one-third of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F2 · balance_after: Includes 14,343 restricted stock units granted on May 4, 2015, which vest on May 4, 2018; 6,836 restricted stock units granted on February 24, 2016, which vest one-half of the total units on February 24, 2018 and one-half of the total units on February 24, 2019; and 6,491 restricted stock units granted on February 22, 2017, which vest one-third of the total units on February 22, 2018, and one-third of the total units on February 22, 2019, and one-third of the total units on February 22, 2020, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F3 · balance_after: Includes 462 shares acquired on November 30, 2017 under the Insulet Corporation 2007 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:08 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 11,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006482 · form4.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,065 F1 · shares: The 11,962 performance share units were granted on February 24, 2016, and the Compensation Committee of the Board of Directors determined on February 13, 2018 that the performance share units were earned based on the performance of the Company. The full award remains subject to time-based vesting in accordance with the following schedule: one-half of the performance share units vest on the second anniversary of the date of grant and one-half of the performance share units vest on the third anniversary of the date of grant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F2 · balance_after: Includes 14,343 restricted stock units granted on May 4, 2015, which vest on May 4, 2018; 6,836 restricted stock units granted on February 24, 2016, which vest one-half of the total units on February 24, 2018 and one-half of the total units on February 24, 2019; and 6,491 restricted stock units granted on February 22, 2017, which vest one-third of the total units on February 22, 2018, and one-third of the total units on February 22, 2019, and one-third of the total units on February 22, 2020, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F3 · balance_after: Includes 462 shares acquired on November 30, 2017 under the Insulet Corporation 2007 Employee Stock Purchase Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 23:39 UTC | INSULET CORP PODD · Entity 3516 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17,058 | $0.00 Strike: $46.22 | $0.00 |
DisclosureSEC source: 0001127602-17-008314 · form4.xml · derivative · entry 2 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,058 Underlying: Common Stock · 17,058 shares Expires 2027-02-22 F3 · derivative.exercise_date: This option is subject to a four-year vesting period with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 23:39 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 6,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-008314 · form4.xml · nonDerivative · entry 1 Levitz Michael L · CIK 0001468019 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,103 F1 · shares: The 6,491 restricted stock units vest one-third of the total units on February 22, 2018, and one-third of the total units on February 22, 2019, and one-third of the total units on February 22, 2020, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F2 · balance_after: Includes 28,686 restricted stock units granted on May 4, 2015, which vest one-half of the total units on May 4, 2017 and one-half of the total units on May 4, 2018; and 6,836 restricted stock units granted on February 24, 2016, which vest one-half of the total units on February 24, 2018 and one-half of the total units on February 24, 2019, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.